Harbour BioMed

Company Overview

Harbour BioMed (HKEX: 02142) is committed to the discovery, development and commercialization of fully human antibody-based medicines targeting both immunological diseases and cancer. The company’s strategy blends internal pipeline programs, strategic in-licensing and co-development partnerships to accelerate global impact.

Harbour’s portfolio spans multiple antibody formats, including conventional monoclonals and heavy chain-only antibodies, as well as engineered bispecifics and next-generation constructs. Its approach supports broad biologic design flexibility and targeted clinical differentiation.

Headquarters and Global Presence

Harbour BioMed maintains a global footprint across multiple innovation hubs, including the US, Europe and China, enabling access to global research, clinical development networks and regulatory engagement. The company runs multinational clinical programs while also supporting regional development and commercialization strategies.

Founding and History

Harbour BioMed was founded in 2016 with the mission to create breakthrough antibody therapeutics. Since inception, it has advanced both internal and partnered programs into clinical development while investing in platform technologies that support efficient discovery and optimization of human biologics.

Therapy Areas and Focus

Harbour’s core focus areas include:

• Oncology, including solid tumors and hematologic malignancies
• Immunology and autoimmune disease
• Inflammation and related pathways

The company’s portfolio includes clinical-stage and preclinical assets designed to address unmet medical needs across these categories using targeted biologic mechanisms.

Technology Platforms and Modalities

Harbour’s discovery engine is built on proprietary antibody platforms that generate diverse fully human binders:

• Harbour Mice® – transgenic mouse platforms producing fully human antibodies in both conventional (H2L2) and heavy chain-only (HCAb) formats
• HBICE® – HCAb-based bispecific immune cell engagers designed to elicit potent tumor killing
• Integrated single-cell technologies and AI-enabled discovery models to accelerate next-generation biologics

These platforms support the design of bispecifics, ADCs and other engineered biologics with optimized therapeutic properties.

Key Personnel

• Jingsong Wang – Founder, Chairman and Chief Executive Officer
• Humphrey Gardner / Yajie Li – Chief Medical Officer (recent leadership enhancement in clinical development)
• Weihao Xu – Chief Financial Officer and Chief Business Officer
• Yiping Rong – Chief Scientific Officer, Executive Director

Strategic Partnerships

Harbour advances its pipeline through targeted global collaborations with pharmaceutical partners and academic institutions. These include co-discovery and co-development agreements, technology licensing for its antibody platforms and strategic alliances to expand clinical reach. Recent collaborations span large-scale biologics discovery and next-generation multispecific programs with industry partners.

FAQ Section